Dehghanian Fariba, Hojati Zohreh, Kay Maryam
Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran.
Avicenna J Med Biotechnol. 2014 Oct;6(4):192-9.
Vascular endothelial growth factor (VEGF-A) is one of the most important regulatory factors in pathological and physiological angiogenesis. Alternative splicing is a complicated molecular process in VEGF-A gene expression which adds complexity to VEGF-A biology. Among all VEGF-A exons, alternative splicing of exon 8 is the key determinant of isoform switching from pro-angio-genic VEGF-xxx to anti-angiogenic VEGF-xxxb. This is known as a key molecular switching in many pathological situations. In fact, the balance between VEGF-xxx and VEGF-xxxb isoforms is a critical controlling switch in both conditions of health and disease. Here, the properties of VEGF-xxx and VEGF-xxxb isoforms were discussed and their regulatory mechanism and their roles in certain pathological processes were evaluated. In summary, it was suggested that C-terminal VEGF-A alternative splicing can provide a new treatment opportunity in angiogenic diseases.
血管内皮生长因子(VEGF-A)是病理和生理血管生成中最重要的调节因子之一。可变剪接是VEGF-A基因表达中的一个复杂分子过程,这增加了VEGF-A生物学的复杂性。在所有VEGF-A外显子中,外显子8的可变剪接是从促血管生成的VEGF-xxx向抗血管生成的VEGF-xxxb亚型转换的关键决定因素。在许多病理情况下,这被认为是一个关键的分子转换。事实上,VEGF-xxx和VEGF-xxxb亚型之间的平衡是健康和疾病状态下的一个关键控制开关。在此,讨论了VEGF-xxx和VEGF-xxxb亚型的特性,并评估了它们的调节机制及其在某些病理过程中的作用。总之,有人提出C端VEGF-A可变剪接可为血管生成性疾病提供新的治疗机会。